REPL
MaterialsReplimune Group Inc
Live · NASDAQ · May 9, Close
What's Moving REPL Today?
No stock-specific AI insight has been generated for REPL yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
REPL News
20 articles- Oncolytics Biotech Reports Data in Colorectal Cancer StudyYahoo Finance·May 6, 2026
- Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingYahoo Finance·Apr 27, 2026
- Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA DecisionYahoo Finance·Apr 17, 2026
- Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design ConcernsYahoo Finance·Apr 15, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Apr 13, 2026
- Top Midday DeclinersYahoo Finance·Apr 13, 2026
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low.Yahoo Finance·Apr 13, 2026
- Sector Update: Health Care Stocks Softer Monday AfternoonYahoo Finance·Apr 13, 2026
- Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock CrashesYahoo Finance·Apr 13, 2026
- Nike downgraded, Starbucks upgraded: Wall Street's top analyst callsYahoo Finance·Apr 13, 2026
- Replimune melanoma therapy rejected by FDA, shares plungeProactive Investors·Apr 13, 2026
- FDA issues complete response letter to Replimune’s RP1 for melanomaPharmaceutical-technology·Apr 13, 2026
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedYahoo Finance·Apr 13, 2026
- FDA Review Looms As Replimune Faces Weak Technical SetupYahoo Finance·Apr 11, 2026
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire Inc.·Apr 10, 2026
- Sector Update: Health Care Stocks Fall Late AfternoonYahoo Finance·Apr 10, 2026
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeYahoo Finance·Apr 10, 2026
- Sector Update: Health Care Stocks Lower Friday AfternoonYahoo Finance·Apr 10, 2026
- RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseYahoo Finance·Mar 30, 2026
- CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian CancerYahoo Finance·Mar 26, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Replimune Group Inc
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.